Tyme-88-Panc Part 2: A randomized phase II/III of SM-88 with MPS as third-line in metastatic PDAC.

Shubham Pant,Sant P. Chawla,Vincent Chung,Giuseppe Del Priore,Dae Won Kim,Marcus Smith Noel,Paul E. Oberstein,Allyson J. Ocean,Philip A. Philip,Vincent J. Picozzi,Diane M. Simeone,Andrea Wang-Gillam

Tyme-88-Panc Part 2: A randomized phase II/III of SM-88 with MPS as third-line in metastatic PDAC.

2020

Shubham Pant
Sant P. Chawla
Vincent Chung
Giuseppe Del Priore
Dae Won Kim
Marcus Smith Noel
Paul E. Oberstein
Allyson J. Ocean
Philip A. Philip
Vincent J. Picozzi
Diane M. Simeone
Andrea Wang-Gillam

TPS789Background: Patients with metastatic pancreatic cancer who have progressed on two prior lines of therapy have a poor prognosis with an overall survival in the range of 2-2.5 months. (Manax, e...

Keywords:

third line
Internal medicine
Oncology
Medicine
Pathology
poor prognosis
overall survival
Metastatic pancreatic cancer

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations